Industry vet joins InCarda as executive chairman

3 April 2019

Daniel Welch, the man who previously headed up several biotechs that were sold to pharma majors over the past several years, has joined privately-held US biopharma company InCarda Therapeutics as executive chairman.

Mr Welch possesses more than 30 years of experience in both multinational pharmaceutical and biotechnology companies.

During his career, Mr Welch has led multiple biopharmaceutical companies that achieved significant value creation during his tenure. He was chairman of AveXis when the company was acquired by Novartis (NOVN: VX) for $8.7 billion in 2018, served as president, chief executive and chairman of InterMune when the company was sold to Roche (ROG: SIX) for $8.3 billion in 2014 and served as chairman and chief executive of Triangle Pharmaceuticals when it was acquired by Gilead Sciences (Nasdaq: GILD) in 2003 for $464 million.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK